Securities Registration: Employee Benefit Plan (s-8)
March 16 2020 - 4:54PM
Edgar (US Regulatory)
As filed with the Securities and Exchange Commission on March 16, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE
SECURITIES ACT OF 1933
Aerpio Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
Delaware
|
|
61-1547850
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
Aerpio Pharmaceuticals, Inc.
9987 Carver Road, Suite 420
Cincinnati, OH
|
|
45242
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
2017 Stock Option and Incentive Plan
Amended and Restated 2017 Employee Stock Purchase Plan
(Full Title of the Plan)
Joseph Gardner
President
Aerpio
Pharmaceuticals, Inc.
9987 Carver Road, Suite 420
Cincinnati, OH 45242
(Name and Address of Agent for Service)
(513) 985-1920
(Telephone Number, Including Area Code, of Agent For Service)
Copies to:
Kingsley L. Taft, Esq.
Danielle M. Lauzon, Esq.
James Xu, Esq.
Goodwin
Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated
filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:
|
|
|
|
|
|
|
Large accelerated filer
|
|
☐
|
|
Accelerated filer
|
|
☐
|
|
|
|
|
Non-accelerated filer
|
|
☒
|
|
Smaller reporting company
|
|
☒
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION
OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
|
Title of Securities
To Be Registered
|
|
Amount
To Be
Registered
(1)
|
|
Proposed
Maximum
Offering
Price
Per Share
|
|
Proposed
Maximum
Aggregate
Offering Price
|
|
Amount of
Registration Fee (6)
|
Common Stock, par value $0.0001 per share
|
|
1,623,520 shares(2)
|
|
$0.60(3)
|
|
$974,112
|
|
$126.44
|
Common Stock, par value $0.0001 per share
|
|
350,000 shares(4)
|
|
$0.51(5)
|
|
$178,500
|
|
$23.17
|
Total
|
|
1,973,520 shares
|
|
|
|
$1,152,612
|
|
$149.61
|
|
|
(1)
|
In accordance with Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act),
this Registration Statement shall be deemed to cover any additional shares of Common Stock that may become issuable under the Registrants 2017 Stock Option and Incentive Plan (the 2017 Plan) and Amended and Restated 2017 Employee
Stock Purchase Plan (the 2017 ESPP) resulting from stock splits, stock dividends, recapitalizations or similar transactions effected without the receipt of consideration which results in an increase in the number of the Registrants
outstanding shares of Common Stock.
|
(2)
|
Represents an automatic increase of 1,623,520 shares of the Registrants Common Stock to the number of
shares available for issuance under the 2017 Plan, effective January 1, 2020. Shares available for issuance under the 2017 Plan were previously registered on a registration statement on Form S-8 filed
with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057), on April 6, 2018 (Registration No. 333-224189) and on
March 7, 2019 (Registration No. 333-230114).
|
(3)
|
The price of $0.60 per share, which is the average of the high and low sale prices of the Common Stock of the
Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are without
a fixed price.
|
(4)
|
Represents an automatic increase of 350,000 shares of the Registrants Common Stock to the number of
shares available for issuance under the 2017 ESPP, effective January 1, 2020. Shares available for issuance under the 2017 ESPP were previously registered on a registration statement on Form S-8 filed
with the Securities and Exchange Commission on August 18, 2017 (Registration No. 333-220057) and on March 7, 2019 (Registration No. 333-230114).
|
(5)
|
The price of $0.51 per share, which is 85% of the average of the high and low sale prices of the Common Stock
of the Registrant as quoted on the Nasdaq Capital Market on March 10, 2020, is set forth solely for purposes of calculating the registration fee pursuant to Rules 457(c) and (h) of the Securities Act and has been used as these shares are
without a fixed price. Pursuant to the 2017 Employee Stock Purchase Plan, the purchase price of the shares of Common Stock reserved for issuance thereunder will be 85% of the fair market value of a share of Common Stock on the first trading day of
the offering period or on the exercise date, whichever is less.
|
(6)
|
Calculated pursuant to Section 6(b) of the Securities Act.
|
EXPLANATORY NOTE
This Registration Statement on Form S-8 relating to the 2017 Plan and the 2017 ESPP of Aerpio
Pharmaceuticals, Inc. (the Registrant) registers additional securities of the same class as other securities for which the Registrants registration statement filed on
Form S-8 (Registration No. 333-220057) on August 18, 2017 on Form S-8 (Registration No. 333-224189) on April 6, 2018 and on Form S-8 (Registration No. 333-230114) on March 7, 2019, are effective.
Accordingly, the information contained in the Registrants Registration Statement on Form S-8 (SEC File No. 333-220057) is hereby
incorporated by reference pursuant to General Instruction E, except for Item 8. Exhibits with respect to which the Exhibit Index is incorporated herein by reference.
PART II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cincinnati, State of Ohio, on
March 16, 2020.
|
|
|
AERPIO PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Joseph Gardner, Ph.D.
|
|
|
Joseph Gardner, Ph.D.
President and
Principal Executive Officer
|
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of Aerpio Pharmaceuticals, Inc. (the Company), hereby severally constitute and appoint Joseph Gardner
and Regina Marek, and each of them singly, our true and lawful attorneys, with full power to them, and to each of them singly, to sign for us and in our names in the capacities indicated below, any and all amendments (including post-effective
amendments) to this Registration Statement, and all other documents in connection therewith to be filed with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in such capacities to enable the
Company to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
|
|
|
|
|
Signature
|
|
Title(s)
|
|
Date
|
|
|
|
/s/ Joseph Gardner, Ph.D.
Joseph Gardner, Ph.D.
|
|
President, Founder and Director (Principal Executive Officer)
|
|
March 16, 2020
|
|
|
|
/s/ Regina Marek
Regina Marek
|
|
Vice President, Finance (Principal Financial and
Accounting Officer)
|
|
March 16, 2020
|
|
|
|
/s/ Muneer A. Satter
Muneer A. Satter
|
|
Chairman of the Board of Directors
|
|
March 16, 2020
|
|
|
|
/s/ Chau Khuong
Chau Khuong
|
|
Director
|
|
March 16, 2020
|
|
|
|
/s/ Cheryl Cohen
Cheryl Cohen
|
|
Director
|
|
March 16, 2020
|
|
|
|
/s/ Anupam Dalal, M.D.
Anupam Dalal, M.D.
|
|
Director
|
|
March 16, 2020
|
|
|
|
/s/ Caley Castelein, M.D.
Caley Castelein, M.D.
|
|
Director
|
|
March 16, 2020
|
|
|
|
/s/ Pravin Dugel, M.D.
Pravin Dugel, M.D.
|
|
Director
|
|
March 16, 2020
|
|
|
|
/s/ Steven Prelack
Steven Prelack
|
|
Director
|
|
March 16, 2020
|
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aerpio Pharmaceuticals (NASDAQ:ARPO)
Historical Stock Chart
From Apr 2023 to Apr 2024